Open AccessHPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM
Author(s) -
Karien C.M. Gosens,
Ramon P van der Zee,
Matthijs L. Siegenbeek van Heukelom,
Vita W. Jongen,
I. Cairo,
Arne van Eeden,
Carel J. M. van Noesel,
Wim Quint,
Hella Pasmans,
Marcel G. W. Dijkgraaf,
Henry J. C. de Vries,
Jan M. Prins
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002928
Subject(s) - medicine , anal cancer , men who have sex with men , placebo , vaccination , randomized controlled trial , confidence interval , intention to treat analysis , surgery , gastroenterology , human immunodeficiency virus (hiv) , cancer , immunology , syphilis , pathology , alternative medicine
Anal cancer precursor lesions high-grade anal intraepithelial neoplasia (HGAIN) are highly prevalent among HIV+ MSM. Treatment of HGAIN is frustrated by high recurrence rates. We investigated the efficacy of the quadrivalent human papillomavirus (qHPV) vaccine as posttreatment adjuvant in preventing HGAIN recurrence in HIV+ MSM.